| Literature DB >> 28588309 |
Shuanghong Jiang1, Shan Xie1, Dan Lv1, Pu Wang1, Hanchang He2, Ting Zhang1, Youlian Zhou1, Qianyun Lin1, Hongwei Zhou3, Jianping Jiang4, Jing Nie4, Fanfan Hou4, Ye Chen5.
Abstract
We evaluated differences in the compositions of faecal microbiota between 52 end stage renal disease (ESRD) patients and 60 healthy controls in southern China using quantitative real-time polymerase chain reaction (qPCR) and high-throughput sequencing (16S ribosomal RNA V4-6 region) methods. The absolute quantification of total bacteria was significantly reduced in ESRD patients (p < 0.01). In three enterotypes, Prevotella was enriched in the healthy group whereas Bacteroides were prevalent in the ESRD group (LDA score > 4.5). 11 bacterial taxa were significantly overrepresented in samples from ESRD and 22 bacterial taxa were overrepresented in samples from healthy controls. The butyrate producing bacteria, Roseburia, Faecalibacterium, Clostridium, Coprococcus and Prevotella were reduced in the ESRD group (LDA values > 2.0). Canonical correspondence analysis (CCA) indicated that Cystatin C (CysC), creatinine and eGFR appeared to be the most important environmental parameters to influence the overall microbial communities. In qPCR analysis, The butyrate producing species Roseburia spp., Faecalibacterium prausnitzii, Prevotella and Universal bacteria, were negatively related to CRP and CysC. Total bacteria in faeces were reduced in patients with ESRD compared to that in healthy individuals. The enterotypes change from Prevotella to Bacteroides in ESRD patients. The gut microbiota was associated with the inflammatory state and renal function of chronic kidney disease.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28588309 PMCID: PMC5460291 DOI: 10.1038/s41598-017-02989-2
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Clinical parameters among ESRD patients and healthy controls.
| characteristics | ESRD (n = 52) | controls (n = 60) |
|
|---|---|---|---|
| Age (years) | 51.58 ± 18.33 | 52.53 ± 13.98 | 0.746 |
| sex, male (female) | 29 (23) | 25 (35) | 0.184 |
| BMI (kg/m^2) | 22.52 ± 2.74 | 21.64 ± 3.25 | 0.098 |
| CysC (mg/L) | 6.74 ± 3.84 | 0.91 ± 0.14 | 0.000** |
| BUN (mmol/L) | 26.65 ± 10.38 | 5.24 ± 1.54 | 0.000** |
| Scr (μmol/L) | 654.36 ± 174.86 | 76.57 ± 26.89 | 0.000** |
| eGFR (ml/min/1.73 m2) | 6.86 ± 2.87 | 98.03 ± 27.32 | 0.000** |
| CRP (mg/L) | 19.20 ± 40.64 | 1.93 ± 2.58 | 0.005** |
| LPS (EU/mL) | 0.11 ± 0.05 | 0.08 ± 0.04 | 0.033* |
| glucose (mmol/L) | 5.45 ± 1.46 | 4.78 ± 0.60 | 0.089 |
| TG (mmol/L) | 1.71 ± 1.31 | 1.61 ± 1.21 | 0.669 |
| CHOL (mmol/L) | 4.80 ± 1.49 | 4.61 ± 0.69 | 0.831 |
| VLDL (mmol/L) | 0.79 ± 0.51 | 0.61 ± 0.0.45 | 0.134 |
| LDL (mmol/L) | 2.63 ± 1.15 | 2.76 ± 0.59 | 0.749 |
| HDL (mmol/L) | 1.38 ± 0.41 | 1.54 ± 0.41 | 0.194 |
| Lpa (mg/L) | 0.44 ± 0.29 | 0.39 ± 0.21 | 0.066 |
| ApoE (mg/L) | 43.17 ± 20.27 | 39.67 ± 27.00 | 0.697 |
| ApoA, B (mg/L) | 1.33 ± 0.32 | 1.45 ± 0.43 | 0.146 |
In this experiment, patients with diabetes and hyperlipidemia were excluded. Abbrevitions: CKD, Chronic kidney disease; BMI, body mass index; Scr, serum creatinine; CysC, Cystatin C; BUN, Blood Urea Nitrogen; eGFR, estimated glomerular filtration rate. CRP, C-reactive protein; LPS, Lipopolysaccharide; TG, Triglyceride; CHOL, Cholesterol; VLDL, very low-density lipoprotein; LDL, low-density lipoprotein; HDL, high density lipoprotein; Lpa, lipoproteins a; ApoE, apolipoprotein E; ApoA, B, apolipoprotein A, B *p < 0.05, **p < 0.01. mean ± SD.
Primers used for qPCR in this study.
| Target Bacteria | Primer | Sequence (5′ to 3′) | Annealing (°C) | Product | Reference |
|---|---|---|---|---|---|
| Universal bacteria | Univ-F | AGAGTTTGATCATGGCTCAG | 55 | 540 |
|
| Univ-R | ACCGCGACTGCTGCTGGCAC | ||||
|
| E. col-F | GTTAATACCTTTGCTCATTGA | 55 | 340 |
|
| E. col-R | ACCAGGGTATCTAATCC | ||||
| Bacteroides fragilis group | Bfra-F | ATAGCCTTTCGAAAGRAAGAT | 50 | 501 |
|
| Bfra-R | CCAGTATCAACTGCAATTTTA | ||||
| Enterococcus spp. | Ente-F | CCCTTATTGTTAGTTGCCATCATT | 61 | 144 |
|
| Ente-R | ACTCGTTGTACTTCCCATTGT | ||||
| Lactobacillus group | Lact-f | AGCAGTAGGGAATCTTCCA | 58 | 341 |
|
| Lact-R | CACCGCTACACATGGAG | ||||
| Bifidobacterium | Bifid-F | CTCCTGGAAACGGGTGG | 55 | 549–563 |
|
| Bifid-R | GGTGTTCTTCCCGATATCTACA | ||||
| Clostridium coccoides group | Ccoc-F | AAATGACGGTACCTGACTAA | 50 | 438–441 |
|
| Ccoc-R | CTTTGAGTTTCATTCTTGCGAA | ||||
| Faecalibacterium prausnitzii | Fae-F | GGAGGAAGAAGGTCTTCGG | 60 | 248 |
|
| Fae-R | AATTCCGCCTACCTCTGCACT | ||||
| Roseburia spp. | Ros-F | GCGGTRCGGCAAGTCTGA | 60 | 81 |
|
| Ros-R | CCTCCGACACTCTAGTMCGAC | ||||
| Prevotella | Pre-F | GAAGGTCCCCCACATTG | 103 | 60 |
|
| Pre-R | CGCKACTTGGCTGGTTCAG |
Figure 1Principle Coordinate Analysis (PCoA) of gut microbiota from ESRD (Green) and healthy control (Red). The first two axes of the principal coordinate analysis are represented with principal coordinate axis 1 (15.99% variability) and principal coordinate axis 2 (6.69% variability).
Figure 2Relative abundance of the gut microbiota in this study. Microbiome composition in human from controls (n = 26) or patients with ESRD (n = 27). The composition is based on 16S rRNA sequecing. Results are shown at the (A) phylum and (B) genus level. The figure shows species median relative abundance >= 1% of total abundance in either the healthy control group or the ESRD group, and value < 1%, unclassified, unidentified are classified as Others.
Figure 3Indicator microbial groups within the three groups of individuals with logarithmic linear discriminant analysis (LDA) score higher than 2 determined by effect size (LefSe). (A) Histogram of the LDA scores computed for differentially abundant bacterial taxa between healthy controls and patients with ESRD. (B) Cladograms of bacterial lineages with significantly different representation in humans with or without ESRD. Lineages on the bacterial trees are color-coded to indicate whether the taxon does (red or green) or does not (yellow) significantly differ between sample classes. Of those, 11 bacterial taxa were significantly overrepresented in samples from ESRD (green) and 22 bacterial taxa were overrepresented in samples from healthy control (red). Prevotella (red) were significantly overrepresented in control and Bacteroides (green) were overrepresented in ESRD patients. The producing butyrate bacterial taxa (Roseburia, Faecalibacterium, Prevotellaceae, Prevotella, and Coprococcus) was under-abundant in ESRD patients.
Figure 4Canonical Correspondence Analysis (CCA) illustrating relations between bacteria taxa and internal environmental parameters accumulated in healthy controls and patients with ESRD in China. Arrows indicate the direction and magnitude of internal environmental parameters associated with bacterial community structure. The explained variance of the principal axes [Axis 1 (horizontally) and Axis 2 (vertically)] are 9.319% and 6.008%, respectively; The species explained 39.82% of the total information amount. The filled circle represents samples, triangle represents species. S* and C* represent ESRD patients and healthy controls respectively.
Figure 5Bacterial groups quantified by qPCR expressed as log10 bacteria per gram of stool. qPCR for the common micropopulation in control subjects and ESRD patients. Black and white bars represent ESRD patients and healthy controls respectively. Independent-samples T Test was used to evaluate statistical difference between the two groups. *p < 0.05, **p < 0.01.
Correlation analysis of CRP, CysC, BUN, creatinine, eGFR values and the species count determined by qPCR.
| Roseburia spp. | Faecalibacterium prausnitzii | Clostridium coccoides group | Lactobacillus group | Bifidobacterium | Bacteroides fragillis |
| Enterococcus | prevotella | Universal | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| CRP | r | −0.452** | −0.431** | −0.289** | −0.085 | −0.303** | −0.277* | −0.295 | −0.062 | −0.480** | −0.438** |
| p | 0.001 | 0.002 | 0.008 | 0.447 | 0.005 | 0.015 | 0.075 | 0.538 | 0.000 | 0.000 | |
| CysC | r | −0.414** | −0.395** | −0.400** | −0.325* | −0.295* | −.0240 | −0.116 | 0.040 | −0.441** | −0.493** |
| p | 0.003 | 0.005 | 0.001 | 0.014 | 0.021 | 0.075 | 0.377 | 0.759 | 0.001 | 0.000 | |
| BUN | r | −0.237 | 0.083 | −0.106 | −0.018 | −0.495** | −0.257** | −0.228* | −0.237* | −0.011 | −0.538** |
| p | 0.082 | 0.545 | 0.268 | 0.851 | 0.000 | 0.008 | 0.024 | 0.012 | 0.935 | 0.000 | |
| creatinine | r | −0.070 | 0.049 | −0.145 | −0.064 | −0.449** | −0.326** | −0.183 | −0.264** | 0.078 | −0.519** |
| p | 0.609 | 0.724 | 0.172 | 0.524 | 0.000 | 0.001 | 0.097 | 0.008 | 0.559 | 0.000 | |
| eGFR | r | 0.295* | 0.117 | 0.243** | 0.039 | 0.466** | 0.260** | 0.159 | 0.190* | 0.287* | 0.511** |
| p | 0.027 | 0.391 | 0.009 | 0.679 | 0.000 | 0.006 | 0.115 | 0.042 | 0.027 | 0.000 | |
| LPS | r | −0.392** | −0.298* | −0.179 | −0.263* | −0.153 | −0.068 | −0.166 | −0.035 | −0.198 | −0.127 |
| p | 0.003 | 0.029 | 0.141 | 0.027 | 0.204 | 0.591 | 0.171 | 0.773 | 0.151 | 0.290 | |
| glucose | r | 0.023 | −0.247 | −0.023 | −0.274 | −0.058 | 0.079 | −0.056 | 0.131 | −0.349 | −0.226 |
| p | 0.906 | 0.189 | 0.892 | 0.095 | 0.727 | 0.663 | 0.742 | 0.433 | 0.054 | 0.167 | |
| ApoE | r | −0.152 | −0.300 | −0.237 | −0.252 | −0.219 | −0.327 | −0.260 | 0.077 | −0.074 | −0.328 |
| p | 0.474 | 0.054 | 0.208 | 0.172 | 0.236 | 0.083 | 0.159 | 0.692 | 0.729 | 0.071 | |
| ApoA, B | r | 0.075 | 0.096 | −0.022 | 0.219 | 0.258 | 0.079 | 0.028 | 0.296 | −0.069 | 0.167 |
| p | 0.728 | 0.661 | 0.909 | 0.119 | 0.67 | 0.684 | 0.883 | 0.119 | 0.749 | 0.370 | |
| Lpa | r | 0.123 | −0.243 | −0.078 | 0.115 | −0.038 | 0.125 | 0.149 | 0.066 | −0.253 | −0.162 |
| p | 0.567 | 0.264 | 0.680 | 0.539 | 0.840 | 0.518 | 0.425 | 0.732 | 0.233 | 0.384 | |
| VLDL | r | −0.132 | −0.145 | 0.039 | 0.155 | −0.011 | 0.161 | −0.076 | 0.263 | −0.104 | −0.042 |
| p | 0.389 | 0.338 | 0.788 | 0.259 | 0.935 | 0.245 | 0.576 | 0.052 | 0.495 | 0.754 | |
| LDL | r | 0.119 | 0.056 | 0.235 | −0.014 | 0.049 | 0.137 | 0.062 | −0.062 | 0.018 | 0.187 |
| p | 0.476 | 0.734 | 0.096 | 0.922 | 0.773 | 0.337 | 0.817 | 0.653 | 0.918 | 0.165 | |
| HDL | r | 0.083 | 0.114 | 0.040 | −0.289 | −0.020 | −0.029 | 0.183 | −0.242 | 0.200 | 0.173 |
| p | 0.586 | 0.464 | 0.771 | 0.159 | 0.880 | 0.437 | 0.178 | 0.875 | 0.187 | 0.581 | |
| TG | r | −0.134 | −0.043 | 0.088 | 0.268 | 0.031 | 0.067 | −0.041 | 0.336* | 0.009 | 0.003 |
| p | 0.564 | 0.780 | 0.520 | 0.063 | 0.897 | 0.635 | 0.763 | 0.021 | 0.955 | 0.984 | |
| CHOL | r | 0.078 | 0.006 | 0.202 | −0.020 | 0.029 | 0.105 | 0.042 | −0.042 | 0.073 | 0.239 |
| p | 0.639 | 0.970 | 0.136 | 0.885 | 0.828 | 0.461 | 0.760 | 0.759 | 0.678 | 0.123 |
Abbrevitions: CysC, Cystatin C; BUN, Blood Urea Nitrogen; eGFR, estimated glomerular filtration rate. Spearman rank correlation were used to evaluate statistical importance: r: correlation coefficient. *p < 0.05, **p < 0.01.